Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aleksandr I. Tyumentsev"'
Publikováno v:
Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 100, Iss 6, Pp 495-510 (2024)
Nowadays, an estimated more than 300 million people live with hepatitis B virus (HBV) infection globally. One of the main goals of the World Health Organization (WHO) is to eliminate viral hepatitis by the year 2030. The study of the pathogenic and i
Externí odkaz:
https://doaj.org/article/d663cab6d0644c8da679b3004e717ba7
Autor:
Marina A. Tyumentseva, Aleksandr I. Tyumentsev, Maria N. Zakharova, Lola S. Askarova, Taras O. Simaniv, Mikhail A. Piradov, Vasily G. Akimkin
Publikováno v:
Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 100, Iss 1, Pp 7-25 (2023)
Introduction. The John Cunningham virus (JCPyV) causes a fatal demyelinating disease of the central nervous system known as progressive multifocal leukoencephalopathy (PML). In healthy people, the JCPyV non-coding control region (NCCR) is not rearran
Externí odkaz:
https://doaj.org/article/1b757ccb8d4143bb922587bdc8cde1d5
Publikováno v:
Журнал микробиологии, эпидемиологии и иммунобиологии, Vol 99, Iss 5, Pp 587-604 (2022)
Understanding the entire pathogenesis of HIV infection, from penetration at the gates of infection to the induction of severe immunodeficiency, is an essential tool for the development of new treatment methods. Less than 40 years of research into the
Externí odkaz:
https://doaj.org/article/e6206a069a7441dd8db8c890544ad801
Publikováno v:
PLoS ONE, Vol 17, Iss 2 (2022)
Background According to the World Health Organization, more than 250 million people worldwide are chronically infected with the hepatitis B virus, and almost 800.000 patients die annually of mediated liver disorders. Therefore, adequate biological te
Externí odkaz:
https://doaj.org/article/64ce04d3c27045839d57d41692c84b36
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background Delivery of CRISPR/Cas RNPs to target cells still remains the biggest bottleneck to genome editing. Many efforts are made to develop efficient CRISPR/Cas RNP delivery methods that will not affect viability of target cell dramatically. Popu
Externí odkaz:
https://doaj.org/article/29be6d3838f34a0492e637a62af0d06e